Synektik Spólka Akcyjna

SNT.WA

Medical - Devices · Healthcare

Exchange

Warsaw Stock Exchange

Winston Score

Winston is happy

A high-quality business with solid fundamentals.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Strong

Growth

Exceptional

Cash Flow

Good

Stability

Exceptional

Valuation

Good

Dividends

Mixed

Track this stock — start free trial

Winston Score History

The full picture

Synektik is a Polish healthcare company that sells and services advanced medical equipment, with a strong focus on robotic surgery systems. Its main product line involves distributing the da Vinci surgical robot — made by Intuitive Surgical — to hospitals across Poland and Central Europe. Synektik is the exclusive distributor of da Vinci systems in Poland, which makes it a key gatekeeper for robotic surgery in the region.

The company earns money in two main ways: selling the robotic systems to hospitals and collecting recurring fees for maintenance, training, and consumable supplies used during each surgery. It operates primarily in Poland, with some presence in neighboring Central European markets. Its exclusive distribution agreement with Intuitive Surgical is its biggest competitive advantage, but it is also its biggest risk — if that agreement were changed or lost, the business would be significantly disrupted. Growth depends heavily on how quickly Polish hospitals adopt robotic surgery, which is still in early stages compared to Western Europe.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+89.5% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+132.4% YoY

YoY Growth Rate

Strong earnings growth

Insider Activity

53.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

93M PLN cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Synektik Spólka Akcyjna grew revenue 89% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

32.4%

Modest — 32.4% gross margin

Profit after running costs

Operating Margin

23.3%

Excellent — 23.3% operating margin

Return on the money invested

ROCE

95.5%

Exceptional — 95.5% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+49.5%

Fast-growing sales (+49.5% YoY)

Profit growth

EPS YoY

+352.7%

Earnings growing fast (+352.7% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

42%

Weak — only 42% of profit becomes cash

Spare cash per sale

FCF Margin

16.4%

Converts sales into free cash efficiently (16.4%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.10

Conservative — low debt load (0.10)

Covers its interest

Interest Cover

35.62x

Comfortably covers interest (35.6x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

7.3x

no trend

Attractive valuation — P/E 7.3

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year

P/E vs Forward

-7.0

SLOWING

Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.98%

no trend

Moderate income — 2.98% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial